Latent membrane protein 1 (LMP1) is an Epstein-Barr virus (EBV)-encoded oncogene expressed in EBV-associated nasopharyngeal carcinoma (NPC). Previous studies indicate that a strategy combining LMP1-mediated NF-kB activation and the HSV thymidine kinase/Ganciclovir (HSVtk/GCV) prodrug system leads to regression of tumor growth in nude mice. To improve the efficacy of this strategy in immunocompetent hosts, we developed a therapeutic cassette, p6kB-EDL1E-tk, containing six copies of the NF-kB binding motif and an epithelial-specific EBV promoter, ED-L1E. The cassette was tested in a murine CT-26 carcinoma model in syngenic Balb/c mice. Coinjection of an LMP1-expressing vector and p6kB-EDL1E-tk by in vivo electroporation in mouse muscle revealed at least two-fold higher TK enzymatic activity than that of previously tested pLTR-tk. Furthermore, growth was attenuated in a group of mice containing LMP1-positive tumors that were intratumorally injected with the p6kB-EDL1E-tk cassette and GCV via in vivo electroporation, but not in mice treated with p6kB-EDL1E-tk or GCV alone. Similarly, no retardation of tumor growth was observed in mice containing LMP1-negative CT-26 tumors injected with both the p6kB-EDL1E-tk cassette and GCV. We propose that intratumoral injection of therapeutic agents, such as DNA of transcription-regulated cassette and GCV, via in vivo electroporation may be used as an alternative treatment for EBV LMP1-expressing cancers.
H uman nasopharyngeal carcinoma (NPC) arises in the epithelium of the posterior nasopharynx. Histologically, NPC is classified by the World Health Organization (WHO) into three types. Type I NPC is a keratinizing squamous-cell carcinoma similar to those that arise from other sites of the head and neck. Type II is a nonkeratinizing epidermoid carcinoma, whereas Type III includes undifferentiated carcinomas. 1 Clinically, Types II and III are the two most prominent diseases in the endemic areas, including Taiwan, the Mediterranean basin, Alaska, and the southern parts of China. 2 NPC is primarily treated with radiotherapy. However, metastasis occurs in 7% of patients at initial diagnosis and 20% or more develop metastasis after treatment, suggesting that supplementary therapy is required.
Epstein-Barr virus (EBV) is a human herpes virus, which infects human B lymphocytes, T lymphocytes, and epithelial cells. EBV is closely associated with NPC, and at least two viral genes are expressed in tumor cells. One of these is the latent membrane protein 1 (LMP1), an integral membrane protein that has a profound effect on the morphology of rodent cells. 3 LMP1 is additionally essential for the in vitro transformation of human primary B lymphocytes and downregulates cytokeratin expression in human epithelial cells. 3, 4 Transgenic mice containing the LMP1 gene develop lymphomas, further supporting a role of LMP1 as a transforming protein. 5, 6 LMP1 is a 62 kDa protein comprising a short cytoplasmic N-terminus of B25 amino acids, a long cytoplasmic C-terminus of B200 amino acids, and six membrane spanning segments. 7 The C-terminal cytoplasmic domain of LMP1 contains at least two major functional regions, CTAR-1 and CTAR-2, which mediate most LMP1-involved signal transduction. CTAR-1 associates with TNF receptor-associated factors (TRAF), 8 while CTAR-2 interacts with the TNF receptor-associated death domain protein, TRADD. 9 Through interactions with TRAF and TRADD, LMP1 induces NF-kB and JNK activation. [10] [11] [12] [13] Furthermore, LMP1 triggers NF-kB activation by inducing the degradation of IkB and facilitating the translocation of NF-kB molecules into the nucleus. 14 This results in the activation of target genes through association of p50/p65 NF-kB molecules with the NF-kB-binding motif located within the upstream regulatory region of promoters.
We previously reported a therapeutic strategy using LMP1-induced NF-kB activation to induce the HSVTK/ GCV prodrug system. 15 The HSVtk gene in the earlier study was expressed from the HIVLTR sequence containing two copies of the NF-kB motif, and activated by NPC-derived LMP1 (NLMP1). 16 Cells expressing both NLMP1 and HSVtk genes were highly sensitive to GCV treatment, and tumors induced in nude mice regressed. To develop a therapeutic program for the treatment of EBVassociated diseases, we constructed a transcriptional cassette containing ED-L1E, a promoter that is preferentially activated in NPC cells, and copies of the NF-kB motif that specifically enhance HSVtk expression by LMP1. Experiments with CT-26 tumors in syngenic Balb/ c mice revealed that the best combination involved the direct delivery of GCV and a therapeutic cassette containing six copies of the NF-kB motif and ED-L1E to LMP1-positive tumors by in vivo electroporation.
Materials and methods

Cell lines
CT-26 is a murine colon adenocarcinoma cell line syngenic to BALB/c mice. NPCTW02 derived from NPC tumor was generously provided by Dr CT Lin (National Taiwan University, Taiwan). C33A (ATCC HTB31) is a human HPV-negative cervical carcinoma cell line. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) (GibcoBRL). LMP1-positive CT-26 cell clones (CT-26-NLMP1) were established by transfection of 2 mg NLMP1-expressing vector, pT7(E) 17 and a neo-containing vector, pSV2neo (Clontech, Palo Alto, CA, USA), followed by selection with G418 (500 mg/ml).
To generate an LMP1-positive cell clone that also expresses the HSVtk gene, CT-26-NLMP1 cells were cotransfected with 1 mg pBabe-Hygro and 10 mg p6kB-EDL1E-tk (see ''Plasmid construction''). Cells were selected using G418 and hygromycin, and maintained in DMEM medium supplemented with 10% FBS, 500 mg/ml G418 and 200 mg/ml hygromycin.
Experimental animals
Male 6-8-week-old BALB/c mice were purchased from the National Laboratory Animal Breeding and Research Center of National Science Council, ROC (Nangang, Taipei, Taiwan). Animals were maintained at the Animal Care Center of Chang-Gung University.
Plasmid construction
Plasmids containing the kB binding motif were generated as follows: two copies of the motif were constructed by annealing two complementary oligonucleotides corresponding to the binding sequence located on HIV-LTR. 18 Briefly, two NF-kB motif-containing primers (primer 1, 5 0 -CTAGTCCCCAGCGGAAAGTCCCTT GT-3 0 and primer 2, 5 0 -CTAGACAAGGGACTTTCCG CTGGGGA-3 0 ) were annealed to generate 2 Â NF-kB binding motif and ligated into SpeI-and XbaI-digested pBluescript II KS (+) (Stratagene, USA). The resulting plasmid was designated pBluescript-2kB. The pBluescript-4kB plasmid containing four copies of the kBbinding motif was generated by the ligation of XmaI-and SacI-digested pBluescript-2kB to SpeI-and ScaI-digested pBluescript-2kB. Similarly, plasmid pBluescript-6kB containing six copies of the kB binding motif was generated by the ligation of XmaI-and SacI-digested pBluescript4kB to SpeI-and ScaI-digested pBluescript-2kB. Plasmid pBluescript-8kB containing eight copies of the kB-binding motif was generated by ligation of XmaI-and SacIdigested pBluescript-4kB to SpeI-and ScaI-digested pBluescript-4kB. The kB-containing luciferase reporter constructs were generated by insertion of DNA fragments from the four pBluescript-kB plasmids containing 2, 4, 6, or 8 binding motifs, respectively, into pEDL1E-Luc. 16 The p2kB-EDL1E-Luc plasmid was generated by inserting two copies of the kB-binding motif obtained from SpeI-and XmaI-digested pBluescript-2kB into the EagI site (B520 bp upstream of the ED-L1E promoter) of the ED-L1E promoter of the EBV LMP1 gene. 16 Similar methods were used to generate p4kB-EDL1E-Luc, p6kB-EDL1E-Luc, and p8kB-EDL1E-Luc. Plasmids p2kB-EDL1E-tk and p6kB-EDL1E-tk were generated by insertion of an B0.8 kb SmaI-BglII fragment (containing two or six copies of the NF-kB-binding motif and ED-L1E promoter) of p2kB-EDL1E-Luc and p6kB-EDL1E-Luc into ClaI-BglII-digested pHSV-106 (GibcoBRL). The pLTR-tk plasmid is described by Wu et al. 15 
DNA transfection
Plasmid DNA was prepared using Nucleobond kits (Macherey-Nagel, Germany). For DNA transfection, 1 Â 10 5 cells in six-well plates were transfected with 2 mg of plasmid DNA by lipofectaminet reagent (GibcoBRL). Cells were harvested 48 hours after transfection and examined using the luciferase activity assay described below.
Tumor induction and growth monitoring
Mice were subcutaneously inoculated with 1 Â 10 5 CT 26-NLMP-1 cells in a total volume of 50 ml. When the tumor reached a measurable size (30-50 mm 3 ), mice were randomly divided into groups of five to seven. Tumor growth was monitored three times a week with a caliper, as soon as treatment commenced. Tumor volume was calculated using the formula: V ¼ a Â b 2 /2, where V represents volume (mm 3 ), a is the maximum tumor diameter, and b is the minimum tumor diameter. 19 
Western blotting
Cells were washed twice with PBS and collected. Following centrifugation at 1500 g for 5 minutes, cell pellets were resuspended and lysed in lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM phenylmethylsulfonyl fluoride, and 1% Triton X-100) by sonication. Supernatants were collected by centrifugation at 12,000 g for 10 minutes, and protein concentration was measured with the Bradford assay (BioRad). Protein samples (200 mg) were resolved on SDS-polyacrylamide gels, transferred to nitrocellular membranes (Hybond) and analyzed using S12 monoclonal antibody against LMP-1 7 and antibody against actin (Santa Cruz). Immunoreactive protein bands were visualized with an enhanced chemiluminescence detection kit (Santa Cruz Biotechnology Inc.).
To detect LMP1, tumor tissues were minced and digested with collagenase and trypsin for 1 hour. Suspended cells were collected and cultured in 500 mg/ml G418-containing medium. Western blotting was performed as described above.
Intramuscular DNA injection and in vivo electroporation
To deliver DNA into muscle tissue, 50 mg closed circular plasmid DNA in 50 ml sterile injectable saline was injected into the left and right hind limb tibial muscle, using an insulin syringe (BD Pharmigen). Following plasmid DNA injection, muscle was pulsed in vivo with a T820 squarewave electroporator (BTX, San Diego), which was fitted with an array of 0.5 cm diameter genetrodes. Six pulses were delivered at a frequency of 1 Hz, with a pulse length of 50 ms and 100 V.
Intratumoral DNA injection and in vivo electroporation
Mice were anesthetized with pentobarbital sodium. An established subcutaneous tumor with a volume of 30-50 mm 3 was injected percutaneously with 50 mg closed circular plasmid DNA in 50 ml sterile injectable saline, using an insulin syringe equipped with a 27-gauge needle (BD Pharmigen). Following plasmid DNA injection, the tumor was pulsed with a T820 square-wave electroporator (BTX, San Diego), which was fitted with an array of six 0.5 cm diameter needle electrodes. For optimization of in vivo electroporation condition, specified voltage and pulse conditions were used (Fig 4 legend) . The most efficient condition was that with one 50 ms pulse delivered at a frequency of 1 Hz and 150 V.
For intratumoral delivery of plasmid DNA, plasmids with or without GCV were delivered into the tumor by in vivo electroporation, as described previously. Administration was performed five times every other day and tumor growth was monitored until day 20.
Luciferase assay
After DNA transfection (48 hours), cells were washed, lysed in 100 ml of lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM 1,2-diaminocyclohexane-N,N,N 0 ,N 0 -tetraacetic acid, 10% glycerol, Triton X-100, and 2 mM DTT), and mixed by vortexing. The supernatant was collected by centrifuging at 12,000 g for 10 minutes, and the protein concentration estimated using the Bradford assay (BioRad) in a spectrophotometer (SHIMADZU UV-160A) at OD 595 . Luciferase assay buffer (100 ml) (20 mM tricine, 1.07 mM (MgCO 3 ) 4 Mg(OH) 2 Á 5H 2 O, 2.67 mM MgSO 4 , 0.1 mM EDTA, 33.3 mM DTT, 270 mM coenzyme A, 470 mM luciferin, and 530 mM ATP) was mixed with the same amount of protein from the supernatant and the relative light unit (RLU) was measured using an Autolumat LB953 (Berthold, Germany).
To determine the luciferase activity in muscle, DNA was delivered by in vivo electroporation as described above. Mice were killed by cervical dislocation at 1, 2, or 30 days after electroporation, and the treated region was homogenized in 100 ml PBS in liquid nitrogen. Protein concentration and luciferase activity of lysates were measured. The RLU was determined using an Autolumat LB953 (Berthold, Germany).
Thymidine kinase activity assay
At 2 days after plasmid DNA injection, mice were killed by cervical dislocation. The required portions of muscle were collected and homogenized in 300 ml lysis buffer (10 mM Tris-HCl, pH 7.5, 10 mM KCl, 2 mM MgCl 2 , 1 mM ATP, 10 mM NaF, 0.5% NP-40 and 10% glycerol) using liquid nitrogen. Supernatants were clarified by centrifugation at 12,000 g for 10 minutes, and quantitated using the Bradford assay (Bio-Rad). Muscle lysate (50 mg) was mixed with 50 ml reaction mixture containing 0.16 M Tris-HCl, pH 7.5, 0.14 mM albumin, 12.6 mM creatine phosphate, 11.2 U/ml creatine phosphokinase, 10 mM [8- H] ganciclovir (GCV) (1000 cpm/pmol), 2 mM ATP, 2 mM MgCl 2 , 7.5 mM NaF, and 1.6 mM DTT. The mixture was incubated at 371C for 30 minutes. A 30 ml sample was spotted onto a Whatman DE-81 filter, washed three times with 95% alcohol and dried. Radioactivity on the filters was measured by a liquid scintillation counter, LS-500OTD (Beckman, Fullerton, CA).
GCV sensitivity assay
For a cell survival assay, CT-26-NLMP1-6-kB-tk cells (10 4 ) were plated into 96-well microplates per well. After 18 hours, the regular medium was replaced with fresh medium containing increasing concentrations (10, 50, 100, 200, 300, 500, and 1000 mg/ml) of GCV in duplicate. The percentage cell survival was determined after 4 days using the Cell Titer 96 AQ ueous Nonradioactive Cell Proliferation Assay kit (Promega), according to the manufacturer's instructions. Cell absorption in each well was measured with an MR5000 microwell plate reader (DYNATCH Laboratory, Chantilly, VI) at 450 nm. The percentage of cell survival was calculated using the equation: % cell survival ¼ (absorption of GCV-treated cells/absorption of control cells) Â 100%.
Statistical analysis
Statistical evaluations of the qualitative variables were performed using the Fisher's exact probability test. The mean volume of tumors in the control group, minus 2 Â SD (standard deviation), was used as the cutoff value. Statistical significance was defined at Po.05.
Results
Activation of custom-made kB motif-containing transcriptional cassettes by LMP1 in human carcinoma cells
To determine whether the genetically engineered transcriptional cassettes containing the specified copies of the NF-kB-binding motif and epithelial-specific EBV promoter (ED-L1E) were inducible by LMP1, the LMP1-expressing vector was cotransfected with transcriptional cassettes into NPCTW02 and C33A cells, respectively. The activity of promoter constructs was determined by the luciferase assay. In NPCTW02 cells, the 2kB-containing cassette and promoter-only construct (pEDL1E-luc) were slightly activated in the presence of LMP1, whereas the 6kB-containing cassette was induced B20-fold (Fig  1a) . LMP1 activated the 4kB-and 8kB-containing cassettes by B12-and B15-fold, respectively. Similar results were obtained with C33A cells, except that the 2kB-containing construct was activated Bthree-fold, compared to pEDL1E (Fig 1b) . Consequently, we selected the 6kB-containing cassette for future studies.
Activation of the custom-made kB motif-containing transcriptional cassettes by LMP1 in CT-26 carcinoma cells
In order to establish a model that permits in vivo testing of this transcription cassette in a mouse carcinoma model, murine CT-26 that induces tumors in syngenic Balb/c mice was used to establish cell clones stably expressing NLMP1. As demonstrated in Fig 2, ED-L1E alone was moderately elevated (Bfour-fold), while the 2kB-containing cassette was activated Bseven-fold. The 4-, 6-and 8kB-containing cassettes were activated B13-, B20-, and B12-fold, respectively, by NLMP1. Similar to parental CT-26 cells, CT-26-NLMP1 induced tumor formation, and palpable tumors appeared around 5-7 days following initial inoculation. Expression of NLMP1 in CT-26-NLMP1 cells and corresponding tumors was shown by Western blot using anti-LMP1 antibody S12 (Fig 2b) .
GCV sensitivity test in vitro
To evaluate HSV-TK/GCV toxicity, five cell clones stably expressing both NLMP-1 and p-6 kB-EDL1E-TK were established. One of these displaying the strongest expression of HSVtk was selected for the GCV sensitivity test. Cells (10 4 ) were plated on the medium without or with increasing doses (10, 50, 100, 200, 300, 500, and 1000 mg/ ml) of GCV. After 4 days, the percentage of living cells was measured using the MTT assay. As shown in Fig 3a, approximately 30% of the cells were killed at 10 and 50 mg/ml GCV. At 100 mg/ml GCV, B70% of the cells were killed. No cells survived, following treatment with GCV at concentrations of 200 mg/ml or higher. The results strongly indicate that CT-26 cells expressing both LMP-1 and HSVTK are highly sensitive to GCV.
Effect of GCV on CT-26-NLMP1-EDL1E-tk tumor growth
To determine the effect of GCV on tumor growth in vivo, CT-26-NLMP1-EDL1E-tk cells were inoculated via s.c. injection. GCV (100 mg/kg body weight) or saline was introduced i.p. at days 2, 4, 6, 8, and 10, respectively. Tumor-free mice were scored everyday. NLMP1-mediated activation of EDL1E-Luc constructs without and with two, four, six, and eight copies of the kB-binding motif in transient transfection experiments. LMP1-expressing vector, pT7(E), and reporter plasmids were cotransfected into NPCTW02 (a) and C33A (b) cells, following which luciferase activity was determined. Reporter plasmid pEDL1E-Luc (ED-L1E) contains only the ED-L1E promoter sequence, p2kB-EDL1E-Luc (2kB) contains two copies of the NF-kB-binding motif, p4kB-EDL1E-Luc (4kB) contains four copies of the NF-kB-binding motif, p6kB-EDL1E-Luc (6kB) contains six copies of the NF-kB-binding motif, and p8kB-EDL1E-Luc (8kB) contains eight copies of the NF-kB-binding motif. Construction of reporter plasmids was described in the Materials and methods. The degree of activation was determined by dividing the luciferase value from cells co-transfected with the NLMP1-expressing vector pT7(E) and indicated promoter constructs with that from cells cotransfected with NLMP1 and pGL2-basic (vector control). Data are the average of at least three independent transfection experiments performed in duplicate. SD is signified by vertical bars. Figure 3b , 60% of the mice (six out of 10) were tumor-free at day 3, while 10% (one out of 10) was tumor-free at day 4, and none was tumor-free at day 5 in the group treated with saline. In contrast, GCV-treated mice remained tumor-free until day 6. Four out of 10 (40%) mice displayed palpable tumors at day 7, six out of 10 (60%) at day 9, and seven out of 10 at day 11 (1 day after termination of GCV treatment). On day 13, the last mouse developed tumor. Our results collectively suggest that GCV treatment attenuates tumor formation in syngenic mice.
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Transgene expression in tissues by in vivo electroporation
To establish an in vivo electroporation protocol, mice muscles were injected with increasing amounts (10, 25, 50, 75 , and 100 mg) of pCMV-Luc in a total volume of 50 ml, with or without in vivo electroporation. To monitor transgene expression, luciferase activity was determined on days 1, 2, and 30. As shown in Fig 4a, transgene activity was detectable in muscles injected with as low as 10 or 25 mg pCMV-Luc, 1 day after in vivo electroporation. At 50 mg or higher concentrations, elevated activity was observed, which was not dose-dependent. The highest activity was detected at day 2 after injection. Transgene expression at day 30 was still detected as B40% of that detected at day 2 at the original injection site (those injected with 50 and 100 mg, respectively). open bars) were exposed to increasing doses of GCV (10, 50, 100, 200, 300, 500, and 1000 mg/ml) and cell viability was determined by the MTT assay after 4 days. Data shown are the average of three independent experiments. SD is represented by vertical bars. (b) Effect of GCV on tumor growth in CT-26-NLMP1-6kB-EDL1E-tk cells. Cells were inoculated via s.c. injection. GCV (100 mg/kg body weight) or saline was introduced i.p. at days 2, 4, 6, 8, and 10, respectively. A total of 10 mice were included in each group and tumor-free mice were scored everyday until day 13.
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Since the method of delivery of transgenes is different between muscle and tumor tissues, pCMV-Luc at a concentration of 2 mg/ml in a total volume of 50 ml was used to determine the optimal conditions for in vivo electroporation of tumors. The results summarized in Figure 4b indicate that the most efficient conditions (represented by the highest luciferase activity) were electroporation at 150 V with 1 electric pulse. Under these in vivo conditions, transgene activity was similar to that expressed in muscle (data not shown).
Thymidine kinase activity in vivo
To ensure that HSVTK functions in mouse tissues and to determine the most suitable HSVtk gene expression cassette for this study, p2kB-EDL1E-tk and p6kB-EDL1E-tk plasmid DNA were injected into muscles of mice by in vivo electroporation, with or without the NLMP1-expressing vector pT7(E). Thymidine kinase activity was assayed at 48 hours following in vivo electroporation. As shown in Fig 5, tissues injected with p6kB-EDL1E-tk displayed Bthree-fold higher TK activity than those treated with p2kB-EDL1E-tk, and Btwofold higher activity than previously examined HIVLTRtk. 15 In vivo effect of a combination of GCV and kB-mediated TK activation on LMP1-expressing tumor growth
To determine the most efficient method of transporting therapeutic agents, p6kB-EDL1E-tk and GCV were delivered into CT-26-NLMP1 tumor tissues, either via in vivo coelectroporation or in vivo electroporation of p6kB-EDL1E-tk and i.p. injection of GCV. Treatment was performed five times every other day until day 10. Notably, no palpable tumors were detected in the coelectroporation group (Fig 6a) . The tumor volume was measured at day 20 following the initial injection. As shown in Fig 6b, tumor growth was significantly suppressed in the group coinjected with p6kB-EDL1E-tk and GCV (100 mg in a volume of 50 ml) when measured at day 10. Tumor growth in mice electroporated in vivo with p6kB-EDL1E-tk and intraperitoneal delivery of GCV (10, 25, 50, 75 , and 100 mg) of pCMV-Luc in a volume of 50 ml were injected into the left and right limb tibial muscles of four mice (n ¼ 8 sites for each treatment or control group). Luciferase activity was detected at 1, 2, and 30 (50 and 100 mg only) days after DNA transfer by in vivo electroporation. (b) Optimization of in vivo electroporation conditions for luciferase expression in tumor tissues. pCMV-Luc (100 mg) in a volume of 50 ml was injected into CT-26-derived tumors (n ¼ 6 mice for each treatment or the control group) at the specified voltage and pulse conditions. Luciferase activity was determined in lysates of tumor tissues, 48 hours after in vivo electroporation. Luciferase activity measured in muscle tissues was included as the control.
Figure 5
In vivo assay of the therapeutic HSVtk/GCV system. TK activity was determined in muscle tissues of mice after electroporation of a combination of plasmids containing HIV-LTR-tk, p2kB-EDL1E-tk, and p6kB-EDL1E-tk, with or without the LMP1-expressing vector (pT7(E)). ''C'' is the vector control of tested promotercontaining plasmids. The data are an average of at least three independent in vivo electroporation experiments.
(100 mg/kg body weight) was moderately reduced (average tumor volume of B150 mm 3 at day 10, compared to B300 mm 3 in untreated controls). Using Fisher's exact probability test, a statistical significance of Po.001 was obtained. The data suggest that the concomitant electroporation of both therapeutic agents leads to significant suppression of tumor growth.
The efficacy of the LMP1-mediated kB-modulated therapeutic strategy was further investigated using coelectroporation of p6kB-EDL1E-tk and GCV. CT-26-NLMP1 and parental CT-26-induced tumors with palpable size (30-50 mm 3 ) were treated as described above, and the mass of tumors was measured at day 20 following initial inoculation. In this study, mice were divided into six groups, each comprising six animals.
Tumors examined in Groups I-IV were derived from CT-26-NLMP1 cells. Mice in Group I were injected with both p6kB-EDL1E-tk and GCV; Group II was inoculated with p6kB-EDL1E-tk; Group III with GCV only; while Group IV was inoculated with 0.9% NaCl solution. Mice of Groups V and VI were derived from CT-26 cells with vector controls. Group V animals were injected with p6kB-EDL1E-tk only, while Group VI mice were injected with 0.9% NaCl solution. In vivo electroporation was performed every other day for 10 days. As shown in Figure 6c , animals intratumorally injected with both p6kB-ED-L1E-tk and GCV (Group I) remained tumorfree at 10 days following initial treatment. Tumors reappeared, but at a more moderate rate (average of tumor volume o200 mm 3 at day 20). NLMP1 tumors injected with GCV (Group III), p6kB-EDL1E-tk only (Group II), or 0.9% NaCl solution (Group IV) displayed no retardation of tumor growth, with tumor volumes ranging from 1200 to 2000 mm 3 . Similarly, no growth retardation was detected in parental CT-26-derived tumors, following treatment with p6kB-EDL1E-tk and GCV (Group V) or with saline (Group VI). Tumor growth was significantly inhibited in Group I animals (Po.01). Thus, the treatment regimen with p6kB-EDL1E-tk and GCV inhibited tumor growth, suggesting the potential to treat LMP1-positive tumors.
Discussion
We previously reported that transcriptional regulation of LMP1-mediated NF-kB activation is a selective therapeutic strategy for EBV-associated diseases. 15 In this study, we improved the system by custom-designing a transcriptional cassette containing an epithelial-specific 5 CT-26-NLMP1 or CT-26 cells to induce tumors. Mice were divided into six groups, each comprising six animals. CT-26-LMP1-induced tumors became palpable at B6 days following inoculation, and were injected intratumorally with p6kB-EDL1E-tk, GCV (100 mg/kg body weight), or both by in vivo electroporation. Tumor volume was determined using a caliper. CT-26-induced tumors were injected with or without both therapeutic agents. The data show tumor sizes at days 10 and 20 after inoculation in Balb/c mice. Tumor volume at day 20 was statistically analyzed. The growth of CT-26-NLMP1 tumors (Group I) was significantly inhibited (Fisher's exact test, Po.01), compared with that in the other five groups (II-IV).
Electroporation-mediated and EBV LMP1-regulated gene therapy Y-h Hsieh et al promoter, ED-L1E, and copies of the NF-kB motif that are specifically activated by LMP1. Following incorporation of this cassette into the HSVTK/GCV prodrug system, we observed that the EBV ED-L1E promoter with six copies of the kB-binding motif effectively and specifically controlled the growth of LMP1-expressing tumors delivered intratumorally via in vivo electroporation. This approach resulted in the regression of LMP-1-positive, but not LMP-1-negative tumors, in a syngenic mouse model. Direct delivery of a regulated therapeutic gene to targeted cells is the ultimate goal of this gene therapy program. LMP1 activates HIV-LTR-regulated HSVtk gene expression via two copies of the NF-kB-binding motif, and tumors expressing LMP1 and HSVTK are sensitive to GCV treatment in nude mice. 15 However, HIV-LTR may not be an ideal promoter to direct the expression of therapeutic genes, as it may integrate into the genome and result in the activation of cellular genes that are initially in an inactivated state. To circumvent this problem, we replaced HIV-LTR with EBV ED-L1E, an upstream promoter of the LMP1 gene. 16 ED-L1E of EBV is a relatively weak promoter that is preferentially activated in EBV-positive NPC tumors and cell lines, 16 but is not active in human B lymphocytes. This is important, since unregulated activation of NF-kB activity in normal human B lymphocyte may result in strong side effects.
To enhance specifically the expression of the therapeutic HSVtk gene, copies of the NF-kB motif were inserted upstream of the transcription initiation site of ED-L1E. LMP1 did not enhance ED-L1E promoter activity, unless copies of the NF-kB binding motif were added to the transcriptional cassette, suggesting that the transcriptional cassette is activated via LMP1-mediated NF-kB activation. This was further demonstrated in the syngenic mouse model, where coinjection of the custom-made NFkB-mediated transcription cassette and GCV via in vivo electroporation into LMP1-expressing tumors suppressed tumor growth. A transcriptionally regulated approach has also been reported for the treatment of other cancers, such as the a-fetoprotein promoter selectively used in gene therapy for hepatoma, tyrosinase promoter in melanoma, carcinoembryonic antigen promoter in adenocarcinoma, Myc-Max responsive elements in small-cell lung cancer, hTERT promoter-induced tumor-specific Bax gene, and caspase-8 expression. [20] [21] [22] [23] [24] [25] To develop the most suitable transcriptional cassette, various copies of the NF-kB motif were examined for efficient activation by LMP1. A dose-dependent effect was observed at two, four, and six copies of the kB motif. A synthetic transcriptional cassette containing the ED-L1E promoter and six copies of the enhancer NF-kB motif displayed strongest promoter activity induced by LMP-1. Interestingly, ED-L1E with eight copies of the kB motif exhibited lower activity than that with six copies of the motif in three cell lines tested (human NPCTW02 and C33A, murine carcinoma CT-26). Since transcriptional activation involves the recruitment of coactivators, this suggests that the local structure of the transcriptional cassette containing the 6kB motif is the most efficient. It is additionally worth noting that the transcriptional cassette established in this study is superior to HIV-LTR, since the activity of p6kB-EDL1E-tk was higher than that of pHIVLTR-tk, which contains two copies of the NF-kB motif (Fig 5) .
Numerous methods have been used to deliver therapeutic DNA into model animals. Among these, direct delivery of therapeutic genes to tumors has several advantages over intravenous injection of naked DNA or viral infection. This is due to the fact that many human or rodent tumors cannot be infected efficiently with adenoviral vectors due to lack of proper receptors. On the other hand, gene transfer by in vivo electroporation, a procedure that involves DNA injection followed by application of electric fields, is effective for introducing DNA into mouse muscle, 26 skin, 27 rat liver, 28 and tumors. 19, 29 Earlier data show that use of in vivo electroporation enhances plasmid DNA uptake in tumor tissue, resulting in expression within the tumor. [30] [31] [32] [33] Furthermore, in vivo electroporation is a safe and nontoxic delivery system. 34 This has been used for the efficient delivery of plasmid DNA encoding chemotherapeutic agents, such as cytokine IL12, resulting in tumor regression, long-term animal survival, and resistance to challenge. 35 In this study, delivery of the therapeutic cassette by in vivo electroporation into LMP1-expressing tumors also showed a therapeutic effect. The best results were obtained upon coinjection of two therapeutic agents, specifically, plasmid DNA of the transcriptional cassette and GCV. In this set of experiments, animals remained healthy in appearance, and two out of six mice completely recovered, indicating that in vivo electroporation of DNA and GCV does not cause side effects.
No significant effects are expected from a therapeutic transgene (HSVtk), if the percentage of the transduced tumor tissue is below 5%. The efficiency of transgene delivery by in vivo electroporation in this study should be at least higher than 5%, since luciferase activity was significantly high at day 2 and still detectable at day 30 following treatment. Thus, in vivo electroporation of naked DNA seems a reasonably feasible approach.
The GCV drug is safe for use, and the HSVtk/GCV prodrug system has been tested clinically for cancer treatment. Phase I/II clinical trials of HSVtk/GCV therapy report that a number of patients achieved partial or complete clinical remission of tumors. [36] [37] [38] Preclinically, tumor-specific killing using the HSVtk/GCV system has been demonstrated in a number of solid tumors, whereby cellular cytotoxicity is induced following GCV administration in animal models. HSVTK converts GCV to a monophosphorylated form, which is then converted to a toxic triphosphate by cellular kinases. GCV triphosphate interferes with DNA synthesis, leading to cell death. Studies in animal models demonstrate that HSVtk/ GCV treatment exerts antitumor effects in various cancers. 15, 19, [39] [40] [41] Direct injection of GCV concurrent with the therapeutic transcriptional cassette appears to have an advantage over delivery via the i.p. method. Tumor growth was significantly regressed in animals treated with therapeutic cassette and GCV via in vivo electroporation, as compared to that treated with a procedure whereby tumors were injected with the therapeutic cassette via in vivo electroporation and GCV intraperitonally (Fig 6b) . In this study, the best results were obtained from experiments involving in vivo electroporation of the therapeutic cassette and GCV directly into the tumors five times every other day over a course of 10 days. The general condition of all the animals examined was satisfactory throughout the study. After a 10-day treatment (a total of five injections), tumors in the test group (group I, in vivo electroporation delivery of both therapeutic gene cassette and GCV) started to regrow. This observation is similar to other studies, 15, 42, 43 suggesting that a small number of tumor cells may have escaped cell cycle control during GCV treatment. 15 The HSVtk/GCV system elicits the bystander effect, which is an important feature and plays a central role in tumor eradication. GCV is converted by HSV-TKexpressing cells into highly toxic GCV phosphates that kill HSV-TK-negative cells, a process known as the bystander effect. 44 However, this may be cell typespecific. [45] [46] [47] [48] It is not clear whether this is effective in the cells examined in this study. This suggests that continuous treatment or a combination with other agents is required for the full regression of tumor growth, consistent with previous reports. For example, ponicidin 49 and topotecan 50 were used to enhance killing and the bystander effect for tumor eradication.
Other strategies for EBV-associated cancer therapy are mainly modulated through EBNA1. EBNA1 upregulates therapeutic gene expression through binding to a transcription enhancer FR (Family of Repeats) located within the oriP rgion of the EBV genome. [51] [52] [53] For example, EBNA-1-mediated FR activity induced p53 gene expression, resulting in the apoptosis of targeted NPC cells. 53 EBV-associated cancers, such as NPC, express both EBNA1 and LMP1 proteins. Therefore, it may be worth examining whether therapy by targeting both proteins is a more efficient supplementary plan for treatment.
In conclusion, we have established a HSVtk-containing therapeutic gene cassette under the control of EBV LMP1. We additionally show that in vivo electroporation of this regulated transcriptional cassette and GCV is sufficient to treat EBV LMP1-positive tumors.
